LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 19, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 10, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Trial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 30, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F18 85 System in pulmonary embolism treatment. LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 13, 2025-- AngioDynamics, Inc.

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 8, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 6, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 6, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 9, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 23, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical

New Codes Expand Market Access to Treatment with the NanoKnife ® System LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 21, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer

LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Multi-center, multi-national study to evaluate mechanical thrombectomy treatment in acute, intermediate-risk PE patients in European Market LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

Regulatory approval enables entry of Auryon Atherectomy System in European market LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system,

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 29, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 8, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market LATHAM, N.Y. --(BUSINESS WIRE)--May 21, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular

New data finds AlphaVac F18 85 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden LATHAM, N.Y. --(BUSINESS WIRE)--May 6, 2024-- AngioDynamics, Inc.